In the ADRIATIC trial, consolidation durvalumab after completion of concurrent chemoradiotherapy (cCRT) for limited-stage small cell lung cancer (LS-SCLC) improved clinical outcomes compared with placebo in the overall study population without evidence of progression post-cCRT. The analysis focused on prespecified subgroups defined by protocol-permitted components of cCRT, receipt of prophylactic cranial irradiation (PCI), and the interval from the end of cCRT to randomization.
In these exploratory subgroup assessments, durvalumab maintained a favorable direction for survival benefits, with reported signals of improved overall survival (OS) and progression-free survival (PFS) relative to placebo across evaluated strata. However, as these analyses are exploratory and based on prespecified subgroup definitions, the extent of benefit and statistical certainty within each subgroup is not stated in the available information.
Uncertainty remains regarding the magnitude of effect within individual subgroups and the interaction between cCRT components, PCI status, and timing from cCRT to randomization. Further details on hazard ratios, confidence intervals, and subgroup-specific outcomes would be required for precise interpretation.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 30 Mar 2026.
The item focuses on Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.
Review the original article for the full source wording and details.